NCT01964924 2019-09-20Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast CancerNational Cancer Institute (NCI)Phase 2 Completed37 enrolled 17 charts
NCT00920257 2017-11-13A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795GlaxoSmithKlinePhase 1 Completed77 enrolled
NCT01138085 2017-11-13Safety, Pharmacokinetics (PK) of AKT and MEK CombinationGlaxoSmithKlinePhase 1 Completed240 enrolled